The ubiquitin–proteasome system in cardiomyopathies-Reference-Cited by-同舟云学术

The ubiquitin–proteasome system in cardiomyopathies

Published:2011-05 Issue:3 Volume:26 Page:190-195
ISSN:0268-4705
Container-title:Current Opinion in Cardiology
language:en
Short-container-title:

Author:

Schlossarek Saskia,Carrier Lucie

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference49 articles.

1. Biochemical mechanisms of cardiac hypertrophy;Morgan;Annu Rev Physiol,1987

2. The ubiquitin-proteasome system: focus on the heart;Zolk;Cardiovasc Res,2006

3. The ubiquitin-proteasome system in cardiac dysfunction;Mearini;Biochim Biophys Acta,2008

4. The E3 ubiquitin ligase specificity subunit ASB2beta is a novel regulator of muscle differentiation that targets filamin B to proteasomal degradation;Bello;Cell Death Differ,2009

5. MYFbx, a novel cardiac-specific e3 ligase, is a component of the sarcomeric z-disk and mediates degradation of α-actinin and filamin c;Busch;Circulation,2009

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacubitril/valsartan reduces proteasome activation and cardiomyocyte area in an experimental mouse model of hypertrophy;Journal of Molecular and Cellular Cardiology Plus;2024-03

2. The accelerated organ senescence and proteotoxicity in thyrotoxicosis mice;Journal of Cellular Physiology;2023-09-26

3. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy;Current Problems in Cardiology;2023-03

4. Sodium fluoride induces skeletal muscle atrophy via changes in mitochondrial and sarcomeric proteomes;PLOS ONE;2022-12-22

5. Protein Quality Control at the Sarcomere: Titin Protection and Turnover and Implications for Disease Development;Frontiers in Physiology;2022-06-30